We use cookies, including third-party cookies from Google to serve personalized ads through AdSense, to operate this site and understand how it is used. By continuing to browse, you accept this use. See our Privacy Policy and Terms of Use for details, including how to opt out of personalized advertising.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: New Software From iCAD Helps Doctors Diagnose Prostate Cancer
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Diagnostics > New Software From iCAD Helps Doctors Diagnose Prostate Cancer
Diagnostics

New Software From iCAD Helps Doctors Diagnose Prostate Cancer

HerinaAyot
HerinaAyot
Share
4 Min Read
The Need-to-Know About Breast Cancer
SHARE

It’s the second most common form of cancer in men, yet diagnosing it still presents a challenge to physicians.

It’s the second most common form of cancer in men, yet diagnosing it still presents a challenge to physicians. Now, new software being used at Englewood Hospital and Medical Center should help detect prostate cancer earlier, eliminate unnecessary testing procedures and help form a treatment plan.

VividLook, a new program used with magnetic resonance imaging exams, makes test results much easier to read and enables physicians to pinpoint where a malignancy may be located in the prostate.

“This is another tool in the approach in the management of prostate cancer,” said Dr. Mark Shapiro, chief of radiology at Englewood. “It will potentially eliminate the need for biopsies in some men and help guide biopsies in others so we will have a lot less false-negative biopsy results.”

More Read

Verisante Technologies Detects Skin Cancer in Less Than A Second
RSNA 2013: What Did We Learn?
Electronic Access Increases Test Ordering Behavior
What To Know About Melanoma Prevention Year-Round
Doctor as Patient

Screening for prostate cancer begins with a digital rectal exam and a blood test that gauges the level of a protein, prostate specific antigen. Typically, a 4 or below is a normal PSA. Patients with higher levels may be urged to get a biopsy.

“But when we don’t have any images to look at, the biopsies are just random samples of different areas,” Shapiro said. “So it’s very easy to miss the cancer.”

In addition to not being very accurate, biopsies are invasive tests that may cause bleeding and infection. Even more distressing, many men undergo the procedure needlessly because most patients with an elevated PSA don’t have prostate cancer. Only 25 percent to 35 percent of the patients who undergo a biopsy with a PSA level between 4 and 9 have the disease, according to the National Cancer Institute.

VividLook should help eliminate the need for so many biopsies and should help physicians find tumors when they exist, doctors said. Before this software was created, doctors didn’t do MRIs on the prostate and had to perform biopsies almost blindly, sometimes taking as many as 12 tissue samples from all areas of the gland with each procedure. That’s because interpreting images of a gland that is filled with numerous veins and arteries and located deep within the pelvic cavity, behind the bladder, was nearly impossible.

“When you inject dye into the prostate, the whole thing kind of glows and it’s hard to distinguish what is suspicious,” said Liza Heapes, a spokeswoman for iCad,Inc., the New Hampshire-based company that makes VividLook.”VividLook uses different criteria and clinical data that show suspicious areas.”

Nearly 218,000 men nationwide are diagnosed with prostate cancer each year and more than 32,000 men die from the disease. About one in six men will be diagnosed with the disease in their lifetime, and it trails lung cancer as the second leading cause of death in men. But more than 2 million men are alive who were diagnosed with the disease at some point in their lives.

Armune Bioscience is an early-stage biopharmaceuticals company focused on the development and commercialization of high value, protein signature-based diagnostic tests for prostate, and other cancers, thereby allowing physicians and patients to make better treatment decisions. Envisioneering Medical Technologies develops a unique and proprietary scanning technology that uses ultrasound imaging to guide diagnostic biopsy sampling and to guide treatment delivery.

Source

 

TAGGED:diagnosticsprostate cancer
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

Flat editorial illustration: Healthcare volunteer communication as a two-way, coordinator-supported process for confirming schedu
How to Manage Volunteer Communication in Healthcare: 5 Tactical Steps and Software Options
Global Healthcare
November 18, 2026
The Nervous System Reset Guide: Simple Ways To Manage Stress -- AI-generated illustration
The Nervous System Reset Guide: Simple Ways To Manage Stress
Infographics Mental Health
November 14, 2026
Flat editorial illustration: A single digital quality-management platform connects document control, electronic approval, audit r
6 Best QMS Software Platforms for ISO 13485 and FDA Part 820 (QMSR)
Global Healthcare Policy & Law
November 12, 2026
Flat editorial illustration: Healthcare editorial illustration about accurate patient intake connecting registration, clinical re
The Role of Patient Data Accuracy in Healthcare Operations
Global Healthcare Policy & Law
November 11, 2026

You Might also Like

healthcare diagnostics research
DiagnosticsTechnology

New Medical Laboratories Are the Key to Diagnostics Research

January 18, 2021
biopharma beat
BusinessDiagnosticsMedical EducationMedical EthicsMedical InnovationsPolicy & LawPublic Health

BioPharma Beat: Is Commercial Support of CME A Bad Idea?

November 24, 2014

Digital Breast Tomosynthesis Brings Benefits to Patient Exams

December 21, 2013

Telomeres Point to New Osteoarthritis Therapies

February 8, 2012
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2026 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?